These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease. Hejazi II; Beg MA; Imam MA; Athar F; Islam A Food Chem Toxicol; 2021 Apr; 150():112057. PubMed ID: 33592201 [TBL] [Abstract][Full Text] [Related]
6. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related]
7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
8. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388 [TBL] [Abstract][Full Text] [Related]
9. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. van de Sand L; Bormann M; Alt M; Schipper L; Heilingloh CS; Steinmann E; Todt D; Dittmer U; Elsner C; Witzke O; Krawczyk A Viruses; 2021 Apr; 13(4):. PubMed ID: 33918301 [TBL] [Abstract][Full Text] [Related]
10. Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants - Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy) - A molecular docking and simulation study. Murugesan S; Kottekad S; Crasta I; Sreevathsan S; Usharani D; Perumal MK; Mudliar SN Comput Biol Med; 2021 Sep; 136():104683. PubMed ID: 34329860 [TBL] [Abstract][Full Text] [Related]
11. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
13. Exploration of Anti-HIV Phytocompounds against SARS-CoV-2 Main Protease: Structure-Based Screening, Molecular Simulation, ADME Analysis and Conceptual DFT Studies. Murali M; Gowtham HG; Shilpa N; Krishnappa HKN; Ledesma AE; Jain AS; Shati AA; Alfaifi MY; Elbehairi SEI; Achar RR; Silina E; Stupin V; Ortega-Castro J; Frau J; Flores-Holguín N; Amruthesh KN; Shivamallu C; Kollur SP; Glossman-Mitnik D Molecules; 2022 Nov; 27(23):. PubMed ID: 36500380 [TBL] [Abstract][Full Text] [Related]
14. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
15. Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation. Nayarisseri A; Khandelwal R; Madhavi M; Selvaraj C; Panwar U; Sharma K; Hussain T; Singh SK Curr Top Med Chem; 2020; 20(24):2146-2167. PubMed ID: 32621718 [TBL] [Abstract][Full Text] [Related]
16. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases. Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022 [TBL] [Abstract][Full Text] [Related]
17. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293 [TBL] [Abstract][Full Text] [Related]
18. An in-silico evaluation of COVID-19 main protease with clinically approved drugs. Tachoua W; Kabrine M; Mushtaq M; Ul-Haq Z J Mol Graph Model; 2020 Dec; 101():107758. PubMed ID: 33007575 [TBL] [Abstract][Full Text] [Related]
19. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239 [TBL] [Abstract][Full Text] [Related]
20. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]